What systemic therapy is recommended for a patient with recurrent metastatic breast cancer in the lungs after prior chemotherapy, given current tumor receptor status and the provided complete blood count results?

Treatment Recommendation for Recurrent Metastatic Breast Cancer with Lung Metastases

The optimal systemic therapy for this patient depends critically on the tumor's HER2 and hormone receptor (ER/PR) status, which must be confirmed from the lung metastases if possible, as receptor status can change between primary and metastatic sites.

Critical First Step: Biomarker Testing

Before initiating any systemic therapy, you must obtain:

• HER2 status (IHC and/or ISH testing) from the lung metastases 1, 2
• ER and PR status from the metastatic tissue 3, 2
• Germline BRCA1/2 mutation testing if not previously done 4, 5
• PD-L1 expression if triple-negative disease is confirmed 4, 5

Important caveat: Receptor status can differ between primary tumor and metastases in up to 20% of cases, making biopsy of the recurrent disease essential for treatment planning 2.

Treatment Algorithm Based on Receptor Status

If HER2-Positive Disease:

The treatment sequence depends on prior trastuzumab exposure:

• If trastuzumab-based adjuvant therapy finished ≥12 months before recurrence: Treat as first-line metastatic disease with pertuzumab + trastuzumab + taxane (preferred, Category 1) 1, 2

• If trastuzumab-based adjuvant therapy finished <12 months before recurrence OR progression on first-line trastuzumab: Use trastuzumab emtansine (T-DM1) as second-line therapy (strong recommendation, high evidence quality) 1

• If already received both pertuzumab and T-DM1: Consider lapatinib plus capecitabine or other HER2-targeted combinations 1

Continue HER2-targeted therapy beyond progression when changing chemotherapy backbone, as this improves outcomes 2.

If HR-Positive, HER2-Negative Disease:

For asymptomatic or slowly progressive lung metastases (which appears to be your case given stable blood counts):

• First-line: CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) + aromatase inhibitor (if postmenopausal) or + ovarian suppression + endocrine therapy (if premenopausal) 6
• Consider fulvestrant if ESR1 mutations are present 4

For symptomatic or rapidly progressive visceral disease: Chemotherapy is preferred over endocrine therapy 3, 7

If Triple-Negative Disease:

The treatment pathway depends on PD-L1 and BRCA status:

1. If PD-L1-positive (≥1% tumor-infiltrating immune cells) and first-line metastatic therapy: Atezolizumab + nab-paclitaxel (preferred, improves OS from 15.5 to 25 months) 5

2. If germline BRCA1/2 mutation-positive: PARP inhibitors (olaparib or talazoparib) are Category 1 preferred options 4, 5

   • Alternative: Platinum agents (cisplatin or carboplatin) if PARP inhibitors unavailable 5

3. If PD-L1-negative or unknown, and BRCA wild-type: Sequential single-agent chemotherapy (taxanes, anthracyclines if not previously used, capecitabine, gemcitabine, or vinorelbine) 3, 7

Regarding Your Blood Count Results

Your CBC shows:

• Mild neutrophilia (80%, absolute 7.52 thou/mm³) - slightly elevated but not contraindication to therapy
• Mild lymphopenia (15%, absolute 1.41 thou/mm³) - borderline low
• Otherwise normal parameters - hemoglobin, platelets adequate

These values indicate you can safely receive systemic chemotherapy or targeted therapy, though close monitoring during treatment is warranted given the borderline lymphopenia. The mild neutrophilia may reflect stress response or early bone marrow involvement, but is not severe enough to delay treatment.

Common Pitfalls to Avoid

1. Do not assume receptor status from primary tumor - always attempt to biopsy metastatic disease 3, 2
2. Do not use combination chemotherapy routinely - sequential single agents have equivalent survival with better quality of life for most patients 3, 7
3. Do not stop HER2-targeted therapy at progression in HER2-positive disease - continue while changing chemotherapy 2
4. Do not delay germline BRCA testing - this opens PARP inhibitor options that significantly improve outcomes 4, 5

Next Steps

1. Obtain tissue diagnosis from lung metastases with full receptor panel
2. Order germline BRCA1/2 testing immediately
3. Assess cardiac function if HER2-positive (baseline LVEF) 1, 8
4. Initiate appropriate systemic therapy based on receptor status as outlined above
5. Enroll in clinical trial if available - this remains a priority for metastatic disease 3